ClinicalTrials.gg
RecruitingNCT05812963FRAME-AMI2Updated Oct 24, 2024

IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI

An interventional study of IVUS-guided PCI group and FFR-guided PCI group in ST Elevation Myocardial Infarction and Non-ST Elevation Myocardial Infarction, sponsored by Samsung Medical Center. Recruiting at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of — 8 open to participants now, 12 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · Korea, Republic of.

Planned enrollment
6th of 28
1,400 · median 314
Started
2023
with 1 other
No phase
14 of 36
5 open now
Primary completion
2028-12
later than 5 of 11 live
Registered
28th of 36
by date
Lead sponsor
5 of 36
Samsung Medical Center

Among the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2023, is one of 14 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 28th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

8 of the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The aim of the study is to compare clinical outcomes between intravascular ultrasound (IVUS)-guided treatment decision versus fractional flow reserve (FFR)-guided treatment decision for non-infarct related artery stenosis in patients with acute myocardial infarction (AMI) and multivessel disease.

Read the detailed description

The treatment of choice of acute myocardial infarction (AMI) including ST-segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI) is reperfusion therapy, preferably with percutaneous coronary intervention (PCI). While need of treating the infarct related artery (IRA) is obvious, need for routine revascularization of non-infarct related artery (non-IRA) has been a topic of debate until recent years. Through a number of observational studies, randomized trials and meta-analyses, the benefits of non-IRA PCI have been continuously implied, and COMPLETE trial with 4041 patients of STEMI and multivessel coronary artery disease in 2019 demonstrated superiority of complete revascularization to culprit-only PCI in terms of cardiovascular death or MI (primary end point) and cardiovascular death, MI, or ischemia-driven revascularization (co-primary end point). As such, complete revascularization of a significant non-IRA stenosis is recommended after successful PCI for IRA in patients with AMI and multivessel disease in current clinical guidelines.

Nevertheless, it has been unclear which criteria should be used to decide non-IRA PCI. Although potential significance of non-IRA lesions can be estimated by angiography, the limitation of angiographic visual assessment or quantitative coronary angiography has been well known. Various measurements are used for incremental information in addition to angiographic assessment in guiding PCI - namely, intravascular ultrasound (IVUS) and fractional flow reserve (FFR). IVUS provides anatomical information regarding the lumen, plaque, and plaque characteristics, and can optimize stent placement minimizing stent-related problems and lead to better clinical outcomes. On the other hand, FFR provides information on amount of ischemia which the stenosis in question is causing, and also improves the quality of PCI which has been demonstrated by multiple previous trials, and current practice guidelines recommend the use of FFR to determine revascularization strategy as Class IA recommendation. Recent trials evaluated comparative prognosis between FFR-guided versus angiograph-guided PCI for non-IRA in patients with acute MI and multivessel disease. FLOWER-MI trial showed comparable clinical outcome between FFR-guided versus angiography-guided PCI for non-IRA in STEMI patients at 1-year follow-up. FRAME-AMI trial showed superiority of FFR-guided PCI over angiography-guided PCI in reducing death, MI, or repeat revascularization during median 3.5 years of follow-up in patients with STEMI or NSTEMI and multivessel disease.

Although IVUS and FFR differ in underlying basic concepts, previous studies demonstrated clinical outcomes following treatment decision by IVUS and FFR was similar between the 2 groups. However, these studies mainly evaluated low-risk stable ischemic heart disease patients with intermediate stenosis, and does not reflect population with acute myocardial infarction undergoing complete revascularization. Currently, the data directly comparing the benefit of IVUS and FFR for non-IRA PCI in AMI is lacking. Considering that coronary atherosclerotic plaque in non-IRA of STEMI patients is associated with significantly higher risk of future clinical events, IVUS would have potential strength of detecting high risk plaque in non-IRA and treatment decision based on plaque characteristics. Conversely, FFR-guided treatment decision for non-IRA would detect functionally significant non-IRA stenosis and treatment decision based on functional significance would reduce unnecessary PCI, as demonstrated by previous trials.

In this regard, randomized controlled trial comparing clinical outcome following non-IRA PCI in AMI patients with multivessel disease guided by IVUS or FFR would provide valuable evidence to enhance patient's prognosis after treatment of STEMI. Therefore, FRAME-AMI 2 trial is designed to compare clinical outcomes after non-IRA PCI using either IVUS-guided or FFR-guided strategy.

03

Conditions studied

  • ST Elevation Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction

Keywords

  • ST-segment elevation MI
  • Fractional flow reserve
  • intravascular ultrasound
  • Multivessel disease
  • Complete revascularization
  • Non-ST Elevation Myocardial Infarction
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 19 years of age
  • Acute ST-segment elevation myocardial infarction (STEMI)

    *STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block

  • Acute non-ST-segment elevation myocardial infarction (NSTEMI)

    *NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:

    1. Symptoms of ischemia.
    2. New or presumed new significant ST-T wave changes
    3. Development of pathological Q waves on electrocardiography.
    4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
    5. Intracoronary thrombus detected on angiography.
  • Successful primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients (In case of NSTEMI, PCI should be performed within 72 hours of symptom onset)
  • Multivessel disease (at least one stenosis of >50% in a non-IRA ≥2.25 mm by visual estimation)
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written prior to any study related procedure.

Exclusion criteria

Exclusion Criteria:

  • Non-IRA stenosis not amenable for PCI treatment by operators' decision
  • Cardiogenic shock (Killip class IV) already at presentation or the completion of IRA PCI
  • Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Pregnancy or breast feeding
  • Non-cardiac co-morbid conditions are present with \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Other primary valvular disease with severe degree: severe mitral regurgitation, mitral stenosis, severe aortic regurgitation, or aortic stenosis
  • Unwillingness or inability to comply with the procedures described in this protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,400 participants (estimated)

Study arms

  • Active comparator
    Fractional flow reserve-guided PCI

    FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.

    Diagnostic Test: FFR-guided PCI group

  • Experimental
    Intravascular Ultrasound-guided PCI

    In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis. According to pre-defined criteria, the decision of revascularization will be made. Revascularization criteria in the IVUS-guided PCI group is 1) minimal lumen area (MLA) ≤ 3mm2 or 2) 3mm2 \< MLA ≤4mm2 and plaque burden \>70%.

    Diagnostic Test: IVUS-guided PCI group

Interventions

  • Diagnostic testIVUS-guided PCI group

    In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.

  • Diagnostic testFFR-guided PCI group

    In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.

06

What researchers measure

Primary outcomes

  1. Patient-Oriented Composite Outcome

    a composite of death, myocardial infarction, or repeat revascularization

    Time frame: 2 years after last patient enrollment

Secondary outcomes

  1. All-cause death

    All-cause death

    Time frame: 2 years after last patient enrollment

  2. Cardiac death

    Cardiac death

    Time frame: 2 years after last patient enrollment

  3. Spontaneous myocardial infarction

    Spontaneous myocardial infarction, defined by Forth Universal definition of myocardial infarction

    Time frame: 2 years after last patient enrollment

  4. Procedure-related myocardial infarction

    Procedure-related myocardial infarction, defined by ARC II definition

    Time frame: 2 years after last patient enrollment

  5. Any revascularization

    Any revascularization (clinically-driven or ischemia-driven)

    Time frame: 2 years after last patient enrollment

  6. Infarct-related artery revascularization

    Infarct-related artery revascularization

    Time frame: 2 years after last patient enrollment

  7. Non-Infarct-related artery revascularization

    Non-Infarct-related artery revascularization

    Time frame: 2 years after last patient enrollment

  8. Definite or probable stent thrombosis

    Definite or probable stent thrombosis

    Time frame: 2 years after last patient enrollment

  9. Stroke (ischemic or hemorrhagic)

    Stroke (ischemic or hemorrhagic)

    Time frame: 2 years after last patient enrollment

  10. Total procedural time

    Total procedural time (from the end of primary PCI for IRA to the completion of non-IRA PCI including amount of staged procedure)

    Time frame: at least 1 week after index procedure

  11. Total fluoroscopy time

    Total fluoroscopy time (from the end of primary PCI for IRA to the completion of non-IRA PCI including amount of staged procedure)

    Time frame: at least 1 week after index procedure

  12. Total amount of contrast use

    Total amount of contrast use (from the end of primary PCI for IRA to the completion of non-IRA PCI including amount of staged procedure)

    Time frame: at least 1 week after index procedure

  13. Incidence of contrast-induced nephropathy

    Incidence of contrast-induced nephropathy, defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure.

    Time frame: at least 1 week after index procedure

  14. A composite of all-cause death or myocardial infarction

    A composite of all-cause death or myocardial infarction

    Time frame: 2 years after last patient enrollment

  15. A composite of cardiac death or non-procedure-related myocardial infarction

    A composite of cardiac death or non-procedure-related myocardial infarction

    Time frame: 2 years after last patient enrollment

  16. Angina severity by Seattle Angina Questionnaire

    Angina severity by Seattle Angina Questionnaire

    Time frame: At 2 years from index procedure

  17. Quality of life by EQ-5D-5L Questionnaire

    Quality of life by EQ-5D-5L Questionnaire

    Time frame: At 2 years from index procedure

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication of main paper.

Access criteria: Executive Committee will discuss to share the de-identified data upon reasonable requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2028, 63 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 63 months is above that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2023
First posted
Apr 14, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05812963
Collaborators
Chonnam National University
Responsible party
Joo-Yong Hahn (Professor, Samsung Medical Center) — Principal investigator
First posted
Apr 14, 2023
Start date
Sep 18, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 24, 2024

Study contacts

Joo Myung Lee, MD, MPH, PhD
Contact
drone80@hanmail.net
82-2-3410-2575
Joo-Yong Hahn, MD, PhD
Contact
jooyong.hahn@gmail.com
82-2-3410-3419
Joo-Yong Hahn, MD, PhD
principal investigator · Samsung Medical Center
Young Joon Hong, MD, PhD
principal investigator · Chonnam National University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion